



Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED)				U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)				Attorney Docket No.	07180/004003		
				Serial No.	09/827,854		
				Applicant	Vassilis I. Zannis et al.		
				Filing Date	April 5, 2001		
				Group	1636		
				IDS Filed	January 20, 2004		
(37 C.F.R. § 1.98(b))				Customer No.	21559		
U.S. PATENTS							
Examiner's Initials	Patent Number	Issue Date	Patentee		Class	Subclass	Filing Date (If Appropriate)
FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION							
Examiner's Initials	Document Number	Publication Date	Country or Patent Office		Class	Subclass	Translation (Yes/No)
OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)							
QN	Chen et al., "Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low density lipoprotein receptor," <i>Molecular Therapy</i> 2:256-261 (2000).						
QN	Gerritsen et al., "Hyperlipidemia in APOE2 transgenic mice is ameliorated by a truncated apoE variant lacking the C-terminal domain," <i>J. Lipid Research</i> 44:408-414 (2003).						
QN	Oka et al., "Long-term stable correction of low-density lipoprotein receptor-deficient mice with a helper-dependent adenoviral vector expressing the very low-density lipoprotein receptor," <i>Circulation</i> 103:1274-1281 (2001).						
EXAMINER	<i>Lynne J. Rogers</i>			DATE CONSIDERED 4/12/074			
EXAMINER: Initial citation <u>considered</u> . Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.							